EMRELIS

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerAdvanced Solid TumorsSmall Cell Lung Cancer

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

EMRELIS

AbbVie

Phase 3

52

Neoadjuvant Therapy

SSun Yat-sen University

Phase 3

23

TY-9591

TTYK Medicines, Inc

Phase 3

24

WX-0593

Qilu Pharmaceutical Co., Ltd.

Phase 3

45

Remeron

OOrganon and Co

Preclinical

16

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Treatment

GSK

Preclinical

110

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer5 trials

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn·AbbVie·Phase 3·NCT06093503

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Active, not recruiting·AbbVie·Phase 2·NCT03539536·270 enrolled

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Terminated·AbbVie·Phase 2·NCT05513703·9 enrolled

Show 2 more trials

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting·AbbVie·Phase 3·NCT04928846·768 enrolled

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting·AbbVie·Phase 2·NCT06568939·150 enrolled

ESS1 trial

Expanded Access to Telisotuzumab Vedotin

Available·AbbVie··NCT04830202

Small Cell Lung Cancer1 trial

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Not yet recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07323641·60 enrolled

Advanced Solid Tumors1 trial

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active, not recruiting·AbbVie·Phase 1·NCT02099058·237 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News